Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-dr5 family antibodies, bispecific or multivalent Anti-dr5 family antibodies and methods of use thereof

a family of anti-dr5 family antibodies and antibody technology, applied in the field of immunology and oncology, can solve the problems of short half-life drawback, achieve stronger agonistic action, induce dr5 apoptosis, and induce apoptosis

Active Publication Date: 2015-05-21
GENMAB BV
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about using two antibodies to induce the cell death pathway in cancer cells. By targeting different parts of the receptors, the antibodies work together like a synergistic agonist, increasing the effect of each other. This combination can lead to a stronger inhibition of cancer cell growth, particularly in glioma, lung, and breast cancers that are resistant to traditional therapies. The antibodies can also be combined with chemotherapy drugs, resulting in a more effective inhibition of cell proliferation. Overall, this patent provides a new and effective treatment method for cancer that targets multiple receptors and enhances the efficacy of existing therapies.

Problems solved by technology

TRAIL polypeptides have been first studied as tolls to induce the TRAIL apoptotic pathway, but has the drawback of a short half-life.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-dr5 family antibodies, bispecific or multivalent Anti-dr5 family antibodies and methods of use thereof
  • Anti-dr5 family antibodies, bispecific or multivalent Anti-dr5 family antibodies and methods of use thereof
  • Anti-dr5 family antibodies, bispecific or multivalent Anti-dr5 family antibodies and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Murine MAb Anti-DR5

[0287]This example illustrates the preparation of hybridoma cell lines secreting anti-DR5 antibodies.

[0288]Antibodies.

[0289]The anti-DR5 antibodies, murine monoclonal antibodies specific for DR5 were produced using standard hybridoma techniques (Zola et al., Aust J. Exp Biol Med Sci. 1981; 59:303-6). Briefly, mice were given i.p. injections of recombinant DR5 (10 μg), (R&D Systems, Lille, France) on weeks 0, 2 and 4. This was followed by an i.v. injection of recombinant DR5 (10 μg) and the splenocytes were fused with mouse myeloma line X63-Ag8.653. Hybridoma supernatants were screened for DR5 binding by ELISA and by flow cytomery on DR5 positive cell lines. A murine MAb panel anti-DR5 noted mDR5-01, mDR5-02, mDR5-04 and mDR5-05 were obtained.

example 2

Cell Culture

[0290]Various tumor-derived cell lines are among the target cells that may be contacted with TRAIL, anti-DR5 MAb alone, MAb combination, in such assay procedures.

[0291]Cell lines. The established human neuroglioma cells H4, HS683 or A172 (available from ATCC) and the established human lung adenocarcinoma cells A549 were grown in Dulbecco's Modified Eagle's Medium (Sigma, St Quentin Fallavier, France) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Sigma, St Quentin Fallavier, France), 4 nM L-glutamine (Sigma, St Quentin Fallavier, France) and 100 U / mL, 100 μg / mL penicillin-streptomycine (Sigma, St Quentin Fallavier, France). The established human glioblastoma astrocytoma cells U87MG or T98G, the human kidney adenocarcinoma cells A704, the human kidney adenocarcinoma cells ACHN and the human breast adenocarcinoma cells MCF7 (available from ATCC) were grown in Eagle's Minimum Essential Medium (Sigma, St Quentin Fallavier, France) supplemented with 10% heat...

example 3

In Vitro Biologic MAb Activity

[0300]This example illustrates methods of evaluating the anti-DR5 MAb impact on TRAIL cellular binding on their ability to trigger cellular cytotoxic effect on cancer cells. These components may be assayed for anti-tumour activity, using any of a number of suitable assays, including but not limited to assays for the ability to slow tumour growth or to kill cancer cells in vitro. Various tumour-derived cell lines are among the target cells that may be contacted with MAb combination, in such assay procedures.

[0301]To identify or select anti-DR5 antibody combination which induce apoptosis, loss of membrane integrity as indicated by, e.g. PI is assessed relative to control (untreated cells) and compared to recombinant TRAIL (FIG. 8). The ability to slow tumour growth is assessed by ATP or BrDU quantification (FIG. 6, FIG. 7). The apoptotic response is assessed by quantification of cleaved caspase 3 (FIG. 9) or cleaved Poly-(ADP-Ribose)-Polymerase (PARP), (F...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.

Description

FIELD OF THE INVENTION[0001]The present invention relates to the fields of immunology, oncology, and more specifically, to monospecific, bispecific or multivalent antibody molecules that can be used to advantage in the treatment of various cancers, autoimmune diseases, infectious diseases that express DR5 antigen. The present invention is related to novel polypeptides binding specifically to the DR5 receptor also called TRAIL receptor 2. The invention relates in particular to a polypeptide having two different binding domains or a combination of polypeptides having these different binding domains, which bind to different epitopes of the DR5 receptor, whereby apoptosis is induced. The invention also relates to pharmaceutical compositions containing these polypeptides and the treatment of cancer, autoimmune diseases and viral infections using these polypeptides and compositions.BACKGROUND OF THE INVENTION[0002]Apoptosis, or programmed cell death, is a physiologic process essential to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/28
CPCC07K16/2878C07K2317/565C07K2317/31C07K2317/569C07K2317/75C07K2317/54C07K2317/55C07K2317/35A61K2039/507C07K2317/56C07K2317/24A61P29/00A61P31/12A61P35/00A61P37/06
Inventor VERMOT-DESROCHES, CLAUDINE BRIGITTE FERNANDESUBIGER, OLIVIER FREDERICBOURDIN, LAURENCE FRANCOISE JEANNE-MARIE
Owner GENMAB BV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com